All compounds discussed on this page are sold by BioPharma for in vitro research purposes only. Not intended for human or veterinary use. This content is for informational purposes and does not constitute medical advice.

If you’re looking for a YK-11 research guide that cuts through the noise and delivers real data on this unique compound, you’re in the right place. YK-11 stands apart from other SARMs — it doesn’t just activate androgen receptors. It disrupts myostatin, the body’s built-in brake on muscle growth. That dual mechanism makes it one of the most compelling research compounds in the performance research space today.

This guide covers YK-11’s mechanism of action, available research data, how it compares to other SARMs, and what Canadian researchers need to know about sourcing and quality.

What Is YK-11? Mechanism of Action Explained

YK-11 is a synthetic steroidal compound that functions as a selective androgen receptor modulator — but with a twist that separates it from everything else in the SARMs category.

Unlike conventional SARMs like RAD-140 or LGD-4033, YK-11 doesn’t just bind androgen receptors and call it a day. Research demonstrates that YK-11 simultaneously:

  • Binds androgen receptors with high affinity, promoting anabolic signaling in muscle tissue
  • Inhibits myostatin production by interfering with follistatin-regulated pathways, removing the genetic limiter on muscle cell growth

Myostatin is a protein encoded by the MSTN gene that acts as a negative regulator of skeletal muscle mass. In simple terms: myostatin tells your body to stop building muscle. YK-11 research suggests it suppresses this signal, which is why it’s frequently discussed in YK11 myostatin studies focusing on muscle cell proliferation.

This dual-action mechanism — androgen receptor agonism plus myostatin inhibition — is what makes YK-11 a standout compound for results-focused studies in the performance research field.

YK-11 Research Data: What the Studies Show

Let’s get into the data. The bulk of YK-11 research comes from in vitro cell culture models, particularly C2C12 myoblast cells (mouse-derived muscle precursor cells). Here’s what the studies report:

Myostatin Suppression Findings

  • YK-11 has been shown to significantly downregulate myostatin mRNA expression in C2C12 cells
  • Follistatin levels — the natural myostatin antagonist — appear to be upregulated in the presence of YK-11
  • The combined suppression of myostatin and elevation of follistatin creates a potent anabolic environment in cell models

Androgenic Activity

  • YK-11 demonstrates strong androgen receptor binding in muscle-derived cells
  • DHT-like gene expression profiles have been observed, suggesting potent anabolic signaling
  • Unlike some SARMs that show tissue-selective partial agonism, YK-11 appears to function as a near-full agonist at androgen receptors in muscle tissue models

Muscle Cell Differentiation

  • Research shows increased myogenic differentiation in YK-11-treated cell cultures
  • Myotube formation and myosin heavy chain expression are elevated compared to controls
  • These findings are consistent with the compound’s myostatin-inhibiting properties

Important caveat: Most YK-11 data is from in vitro models. Human clinical trial data does not exist. All research applications should be limited to validated laboratory settings.

YK-11 vs Other SARMs: How It Compares

YK-11 is often compared to other SARMs, but its dual mechanism puts it in a different conversation entirely. Here’s how it stacks up:

  • YK-11 vs RAD-140: RAD-140 is a pure androgen receptor modulator with strong anabolic data but no myostatin involvement. YK-11 adds the myostatin suppression angle, making it relevant for researchers interested in muscle differentiation pathways beyond standard AR activation.
  • YK-11 vs LGD-4033: LGD-4033 is widely studied for lean mass research. It’s more selective and has more published data. YK-11 is less selective but offers the unique myostatin mechanism.
  • YK-11 vs traditional androgens: YK-11 shares structural similarities with DHT derivatives but was designed to offer more targeted muscle tissue engagement.

For a broader look at the SARMs landscape, see our SARMs research guide.

YK-11 Canada: Sourcing and Quality Considerations

If you’re searching for YK-11 Canada research supply, quality and verification should be your top priorities. The Canadian research compound market has specific considerations:

Purity and Verification

  • Always demand third-party Certificates of Analysis (COA) for any YK-11 research compound
  • Purity below 98% introduces confounding variables into your research
  • BioPharma provides batch-tested, COA-verified YK-11 for research applications

Canadian Regulatory Context

  • YK-11 is sold for in vitro research purposes only in Canada
  • It is not approved for human consumption, medical use, or veterinary application
  • Researchers should ensure compliance with institutional and regulatory guidelines

Storage and Handling

  • Store YK-11 lyophilized powder at -20°C for long-term stability
  • Reconstituted solutions should be used within the timeframe validated by your analytical testing
  • Protect from light and moisture to maintain compound integrity

YK-11 Research Protocols and Dosing Models

While YK-11 has no approved human protocols, the research literature provides direction for in vitro study design:

  • Cell culture concentration ranges in published C2C12 studies typically fall between 10-1000 nM
  • Duration of treatment in published models ranges from 24 to 72 hours for gene expression endpoints, with longer timelines for differentiation assays
  • Solubility in DMSO makes it compatible with standard cell culture methodologies

Researchers designing studies should consult primary literature for specific parameters relevant to their experimental goals. BioPharma’s YK-11 product page provides compound specifications to support protocol planning.

Frequently Asked Questions

What makes YK-11 different from other SARMs?

YK-11 is unique because it combines androgen receptor activation with myostatin inhibition. Most SARMs only target androgen receptors. YK-11’s ability to suppress myostatin — the protein that limits muscle growth — makes it a distinct compound for muscle differentiation and proliferation research.

Is YK-11 available for research in Canada?

Yes, YK-11 is available from BioPharma for in vitro research purposes in Canada. It is sold strictly as a research compound and is not intended for human or veterinary use. Always verify purity with third-party COAs.

What is myostatin and why does YK-11 suppress it?

Myostatin is a protein that negatively regulates skeletal muscle growth. It’s essentially the body’s “muscle brake.” YK-11 research data shows it downregulates myostatin mRNA while upregulating follistatin, the natural myostatin antagonist. This creates conditions favorable for muscle cell growth in research models.

How should YK-11 be stored for research?

YK-11 lyophilized powder should be stored at -20°C and protected from light and moisture. These conditions preserve compound stability and ensure consistent research results across experiments.

Can YK-11 be used for human performance enhancement?

No. YK-11 is sold by BioPharma exclusively for in vitro research purposes. It is not approved for human consumption, dietary supplementation, or veterinary use. There is no clinical safety data supporting human use.

Related Research Guides

Get YK-11 for Your Research

Ready to source high-purity YK-11 for your next study? BioPharma offers batch-tested, COA-verified YK-11 with full transparency on purity and composition.

👉 Shop YK-11 — Lab-Verified Research Compound

All compounds discussed on this page are sold by BioPharma for in vitro research purposes only. Not intended for human or veterinary use. This content is for informational purposes and does not constitute medical advice. These statements have not been evaluated by Health Canada or the FDA.